Immunocore To Tap HTA Advice To Ensure IMCgp100 Success
This article was originally published in Scrip
Executive Summary
British immunotherapy specialist Immunocore Limited plans to make full use of the scientific advice national regulators are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's adaptive pathways pilot program.